ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)

$2.48 -0.06 (-2.3622%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 72

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) News Sources

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

23-04-2026

yahoo.com

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

23-04-2026

yahoo.com

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

27-04-2026

yahoo.com

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

04-05-2026

yahoo.com

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

05-05-2026

yahoo.com

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

08-05-2026

yahoo.com

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

08-05-2026

yahoo.com

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

11-05-2026

yahoo.com

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

11-05-2026

marketbeat.com

Alpha Tau to Participate in May Investor Conferences

18-05-2026

yahoo.com

ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) Sentiment Trend

0 25 50 75 100 73 77 64 72 71 79 74 63 78 73 23-04-2026 27-04-2026 04-05-2026 05-05-2026 08-05-2026 11-05-2026 18-05-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) FAQs

toggle

What is the current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?

The current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is $2.48.


toggle

ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) absolute price change since previous trading day?

The absolute price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is $-0.06.


toggle

ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) percentage price change since previous trading day?

The percentage price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is -2.3622%.


toggle

What is the most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?

The most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is 72 out of 100.


toggle

What is the most recent average sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?

The most recent sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is .


SEC-8K** Filing Available For ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.